1
|
Naddaf R, Carasso S, Reznick-Levi G, Hasnis E, Qarawani A, Maza I, Gefen T, Half EE, Geva-Zatorsky N. Gut microbial signatures are associated with Lynch syndrome (LS) and cancer history in Druze communities in Israel. Sci Rep 2023; 13:20677. [PMID: 38001152 PMCID: PMC10673896 DOI: 10.1038/s41598-023-47723-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 11/17/2023] [Indexed: 11/26/2023] Open
Abstract
Lynch syndrome (LS) is a hereditary cancer syndrome caused by autosomal dominant mutations, with high probability of early onset for several cancers, mainly colorectal cancer (CRC). The gut microbiome was shown to be influenced by host genetics and to be altered during cancer development. Therefore, we aimed to determine alterations in gut microbiome compositions of LS patients with and without cancer. We performed fecal microbiome analyses on samples of LS and non-LS members from the Druze ethnoreligious community in Israel, based on both their LS mutation and their cancer history. Our analysis revealed specific bacterial operational taxonomic units (OTUs) overrepresented in LS individuals as well as bacterial OTUs differentiating between the LS individuals with a history of cancer. The identified OTUs align with previous studies either correlating them to pro-inflammatory functions, which can predispose to cancer, or to the cancer itself, and as such, these bacteria can be considered as future therapeutic targets.
Collapse
Affiliation(s)
- Rawi Naddaf
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Rappaport Technion Integrated Cancer Center, Haifa, Israel
| | - Shaqed Carasso
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Rappaport Technion Integrated Cancer Center, Haifa, Israel
| | | | - Erez Hasnis
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Gastroenterology Institute Rambam Health Care Campus, Haifa, Israel
| | - Amalfi Qarawani
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Rappaport Technion Integrated Cancer Center, Haifa, Israel
| | - Itay Maza
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Gastroenterology Institute Rambam Health Care Campus, Haifa, Israel
| | - Tal Gefen
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
- Rappaport Technion Integrated Cancer Center, Haifa, Israel
| | - Elizabeth Emily Half
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
- Gastroenterology Institute Rambam Health Care Campus, Haifa, Israel.
| | - Naama Geva-Zatorsky
- Technion Israel Institute of Technology the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
- Rappaport Technion Integrated Cancer Center, Haifa, Israel.
- Canadian Institute for Advanced Research, Toronto, ON, Canada.
| |
Collapse
|
2
|
High prevalence of MUTYH associated polyposis among minority populations in Israel, due to rare founder pathogenic variants. Dig Liver Dis 2023:S1590-8658(23)00162-7. [PMID: 36740502 DOI: 10.1016/j.dld.2023.01.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 01/07/2023] [Accepted: 01/09/2023] [Indexed: 02/07/2023]
Abstract
BACKGROUND Autosomal recessive conditions are common in consanguineous populations. Since consanguinity is common in the Israeli Arab population, we evaluated the rate of MUTYH polyposis (MAP) among polyposis patients in this population and studied Pathogenic Variants (PVs) spectrum. METHODS We reviewed health records of all Arab and Druze polyposis patients referred for counseling during 2013-2020 who fulfilled the Israeli Genetic Society criteria for MUTYH/APC testing, in a tertiary center in Northern Israel and four additional gastro-genetic clinics in Israel. RESULTS The Northern cohort included 37 patients from 30 unrelated families; 8(26.6%) carried bi-allelic MUTYH PVs. The major variant p.Glu452del was detected in 6/8 Druze and Muslim families who shared the same haplotype. Other PVs detected in both cohorts included p.Tyr56Ter, p.His57Arg, c.849+3A>C, p.Ala357fs, and p.Tyr151Cys. Among bi-allelic carriers, 88% reported consanguinity, and 100% had positive family history for polyposis or colorectal cancer (CRC). Generally, the age of CRC was 10 years younger than reported in the general MAP population. CONCLUSIONS MAP accounted for 27% of polyposis cases in the Arab population of Northern Israel. PVs spectrum is unique, with high frequency of the founder variant p.Glu452del. Our results may inform the genetic testing strategy in the Israeli Arab population.
Collapse
|
3
|
Goldvaser H, Purim O, Kundel Y, Shepshelovich D, Shochat T, Shemesh-Bar L, Sulkes A, Brenner B. Colorectal cancer in young patients: is it a distinct clinical entity? Int J Clin Oncol 2016; 21:684-695. [PMID: 26820719 DOI: 10.1007/s10147-015-0935-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Accepted: 11/26/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND The incidence of colorectal cancer in young patients is increasing. It remains unclear if the disease has unique features in this age group. METHODS This was a single-center, retrospective cohort study which included patients diagnosed with colorectal cancer at age ≤40 years in 1997-2013 matched 1:2 by year of diagnosis with consecutive colorectal cancer patients diagnosed at age >50 years during the same period. Patients aged 41-50 years were not included in the study, to accentuate potential age-related differences. Clinicopathological characteristics, treatment, and outcome were compared between groups. RESULTS The cohort included 330 patients, followed for a median time of 65.9 months (range 4.7-211). Several significant differences were noted. The younger group had a different ethnic composition. They had higher rates of family history of colorectal cancer (p = 0.003), hereditary colorectal cancer syndromes (p < 0.0001), and inflammatory bowel disease (p = 0.007), and a lower rate of polyps (p < 0.0001). They were more likely to present with stage III or IV disease (p = 0.001), angiolymphatic invasion, signet cell ring adenocarcinoma, and rectal tumors (p = 0.02). Younger patients more frequently received treatment. Young patients had a worse estimated 5-year disease-free survival rate (57.6 vs. 70 %, p = 0.039), but this did not retain significance when analyzed by stage (p = 0.092). Estimated 5-year overall survival rates were 59.1 and 62.1 % in the younger and the control group, respectively (p = 0.565). CONCLUSIONS Colorectal cancer among young patients may constitute a distinct clinical entity. Further research is needed to validate our findings and define the optimal approach in this population.
Collapse
Affiliation(s)
- Hadar Goldvaser
- Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel
| | - Ofer Purim
- Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel.,Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel
| | - Yulia Kundel
- Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel.,Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel
| | - Daniel Shepshelovich
- Department of Medicine A, Rabin Medical Center, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel
| | - Tzippy Shochat
- Statistical Consulting Unit, Rabin Medical Center, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, Israel
| | | | - Aaron Sulkes
- Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel.,Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel
| | - Baruch Brenner
- Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel. .,Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel.
| |
Collapse
|
4
|
Goldberg Y, Barnes-Kedar I, Lerer I, Halpern N, Plesser M, Hubert A, Kadouri L, Goldshmidt H, Solar I, Strul H, Rosner G, Baris H, Peretz T, Levi Z, Kariv R. Genetic features of Lynch syndrome in the Israeli population. Clin Genet 2014; 87:549-53. [DOI: 10.1111/cge.12530] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Revised: 10/22/2014] [Accepted: 10/23/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Y. Goldberg
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - I. Barnes-Kedar
- The Raphael Recanati Genetics Institute; Rabin Medical Center, Beilinson Hospital; Petach Tikva Israel
| | - I. Lerer
- Department of Human Genetics; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - N. Halpern
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - M. Plesser
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - A. Hubert
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - L. Kadouri
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - H. Goldshmidt
- Department of Pathology; Hebrew University, Hadassah Medical School; Jerusalem Israel
| | - I. Solar
- Department of Pathology; Tel Aviv Israel
| | - H. Strul
- Department of Gastroenterology; Tel Aviv Sourasky Medical Center; Tel Aviv Israel
| | - G. Rosner
- Department of Gastroenterology; Tel Aviv Sourasky Medical Center; Tel Aviv Israel
| | - H.N. Baris
- Department of Genetics; Rambam Medical Center; Haifa Israel
| | - T. Peretz
- Sharett Institute of Oncology; Hadassah-Hebrew University Medical Center; Jerusalem Israel
| | - Z. Levi
- Gastroenterology Division, Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
| | - R. Kariv
- Department of Gastroenterology; Tel Aviv Sourasky Medical Center; Tel Aviv Israel
| |
Collapse
|